Search Results

AGCBiologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, and BioConnection, a specialized contract manufacturing organization focusing on aseptic filling of vials and syringes for clinical and commercial production, announced a new strategic partnership.

Galectin Therapeutics Inc. announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference.

XOMA Corporation, the biotech royalty aggregator, announced that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Disc Medicine, Inc. announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET.

Compass Therapeutics, Inc. announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.

Akebia Therapeutics®, Inc. announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY.

Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.